# Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809

> **NCT00437632** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 104 (actual)

## Conditions studied

- Substance Dependence

## Interventions

- **DRUG:** GSK598809
- **DRUG:** Placebo
- **DRUG:** Caffeine

## Key facts

- **NCT ID:** NCT00437632
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03-01
- **Primary completion:** 2008-08-22
- **Final completion:** 2008-08-22
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2017-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00437632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00437632, "Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00437632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*